Navigation Links
Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers
Date:9/18/2012

CAMBRIDGE, Mass., Sept. 18, 2012 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that research evaluating two novel compounds for advanced cancers, including breast, ovarian, gastric and bladder, will be presented at the ESMO 2012 Congress (European Society for Medical Oncology ), Sept. 28 – Oct. 2 in Vienna, Austria. The medicines are some of the first therapies developed using Merrimack's proprietary scientific approach – Network Biology – focusing not on gene expression but on underlying cancer signals that trigger tumor growth.

"At Merrimack Pharmaceuticals, we believe the key to finding new treatment options for cancer is to start closer to the source of the problem – with signals in the cancer cell that turn specific processes on and off, triggering tumor growth and drug resistance," said Robert J. Mulroy, President and Chief Executive Officer, Merrimack Pharmaceuticals. "By charting and modeling these molecular pathways and signals, we can identify the most sensitive points from which to attack the cancer and then develop medicines and companion diagnostics to disrupt or slow tumor growth."

Therapy and Poster Overview:

  • MM-121 is a fully human monoclonal antibody that binds to ErbB3, a protein central to the development of drug resistance and tumor growth in numerous cancers, including ovarian, breast and lung tumors. It is designed to block the signal that allows ErbB3 to bind with other proteins and trigger cell growth and drug resistance.
    • A Phase 1 Study of the Anti-ErbB3 Antibody MM-121 in Combination with Weekly Paclitaxel in Patients with Advanced Gynecological and Breast Cancers (Abstract #: 974PD)
      • Presentation: Gynecological Cancers, Sunday, Sept. 30, 2012, 1:00PM – 2:00PM CET, Hall G
  • MM-111 is a bispecific antibody designed to target cancer cells that are characterized by overexpression of the ErbB2 (HER2) cell receptor. MM-111 is designed to uniquely address the tumor growth and survival signaling promoted by the ErbB2, ErbB3 and heregulin signaling complex.
    • A Phase 1 Study of MM-111; a Bispecific HER2/HER3 Antibody Fusion Protein, Combined with Multiple Treatment Regimens in Patients with Advanced HER2 Positive Solid Tumors (Abstract #: 496P)
      • Poster Session: Poster Presentation III, Monday, Oct. 1, 2012, 1:00PM – 2:00PM CET, Hall XL

About Merrimack Pharmaceuticals, Inc.

Merrimack Pharmaceuticals is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has five targeted therapeutic oncology candidates in clinical development.

Forward-Looking Statement

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

Contact:
Kathleen Petrozzelli Gallagher, Merrimack, 617-441-1043, kgallagher@merrimackpharma.com

Liz Bryan, Spectrum, 202-955-6222, lbryan@spectrumscience.com


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
2. MD Anderson Cancer Center joins Actinium Pharmaceuticals (API) Multicenter Actimab-A Trial
3. Lexicon Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
4. Walgreens Joins with Ferring Pharmaceuticals Inc. to Offer Products and Resources to Women Facing Fertility Complications from Cancer Treatment
5. Isis Pharmaceuticals To Present At Two Upcoming Investor Conferences
6. Onyx Pharmaceuticals To Present At Upcoming Investor Conferences
7. Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics: Twease.org
8. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
9. Mangrove Partners Sends Letter to Stockholders of Nabi Biopharmaceuticals
10. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
11. Avanir Pharmaceuticals Reports Fiscal 2012 Third Quarter Financial And Business Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ... 20, 2017 , ... NetDimensions appoints Bill Mastin, a learning technology veteran, as ... experience in the learning technologies industry, Mastin joins NetDimensions from the New York office ... (LTG). At LEO, Mastin served as SVP of the North America offices and prior ...
(Date:4/20/2017)... (PRWEB) , ... April 20, 2017 , ... ... light sources for advanced technology applications, announced today that Chief Executive Officer (CEO) ... , SEMI is the global industry association connecting the electronics manufacturing ...
(Date:4/20/2017)... ... April 20, 2017 , ... ... unique intellectual property (IP) sharing and commercialization model. , The Center for Advancing ... main component of this effort is bringing the IP to the attention of ...
(Date:4/20/2017)... HACKENSACK, N.J. and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell technologies ... Chief Executive Officer, will present at the Alliance for Regenerative ... Investor Day on Thursday, April 27, 2017 at 09:40 EDT ... Dr. Ralph Kern , MD, MHSc, Chief Medical Officer ...
Breaking Biology Technology:
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 8.8% over the next decade to reach approximately $14.21 ... market estimates and forecasts for all the given segments on global ...
(Date:3/22/2017)... 21, 2017 Optimove , provider ... retailers such as 1-800-Flowers and AdoreMe, today announced ... and Replenishment. Using Optimove,s machine learning algorithms, these ... and replenishment recommendations to their customers based not ... of customer intent drawn from a complex web ...
(Date:3/20/2017)... HANOVER, Germany , March 20, 2017 At ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the ... Japan is this year,s CeBIT partner country. At the largest ... important biometrics in use: fingerprint, face and iris recognition as well as ... ...
Breaking Biology News(10 mins):